Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT) and BlinkRx,
the leading patient access solution, today announced a
collaboration to support healthcare professionals and their
patients undergoing treatment with Otrexup. This prescription
medication is a drug device combination single-dose, once-weekly,
auto-injector containing methotrexate for subcutaneous injections.
BlinkRx's program helps reduce barriers patients may encounter in
having access to their medications. Patients benefit from
transparent low prices, free home delivery, and world-class
support.
BlinkRx is incredibly easy to use for both patients and
providers. When providers send a prescription to BlinkRx, their
patient immediately receives a text with their lowest available
price, including any eligible copay support. Patients can check out
securely online or by phone. Otrexup will be delivered with no
shipping fees.
“We are thrilled to partner with a leading digital pharmacy
provider in BlinkRx that offers a compelling, convenient option and
which aligns to our strategy of leveraging our digital platform and
virtual engagement to better serve our patients,” said Dan Peisert,
President and Chief Executive Officer of Assertio. “This builds
upon our existing pharmacy hub capabilities with a new direct to
patient model for those who prefer a convenient digital
option.”
About Otrexup
Otrexup is a single-dose auto-injector containing a prescription
medicine, methotrexate. Methotrexate is used to:
- Treat certain adults
with severe, active rheumatoid arthritis, and children with active
polyarticular juvenile idiopathic arthritis (pJIA), after treatment
with other medicines including non-steroidal anti-inflammatory
drugs (NSAIDS) have been used and did not work well.
- Control the symptoms
of severe, resistant, disabling psoriasis in adults when other
types of treatment have been used and did not work well.
Otrexup should not be used for the treatment of cancer.
Otrexup should not be used for the treatment of children with
psoriasis.
Otrexup can cause serious side effects
that can lead to death, including
organ system toxicity
People who use methotrexate for the treatment of cancer,
psoriasis, or rheumatoid arthritis, have an increased risk of death
from organ toxicity. Types of organ toxicity can include
gastrointestinal, bone marrow, liver, immune system, nerve, lung,
kidneys, or skin.
Your doctor will do blood tests and other types of tests before
you take and while you are taking Otrexup to check for signs and
symptoms of organ toxicity. Call your doctor right away if you have
any of the following symptoms of organ toxicity: vomiting,
diarrhea, mouth sores, fever, confusion, weakness, temporary
blindness, seizures, headache, back pain, neck stiffness,
paralysis, irritability, sleepiness, problems with coordination,
dry cough, trouble breathing, or severe skin rash.
Women who are pregnant are at increased risk for death
of the baby and birth defects.
Women who are pregnant or who plan to become pregnant must not
take Otrexup. A pregnancy test should be performed before starting
Otrexup. Contraception should be used by both females and males
while taking Otrexup. Pregnancy should be avoided if either partner
is receiving Otrexup for a minimum of 3 months after treatment with
Otrexup for males or during and for 6 months after treatment with
Otrexup for females.
Do not use Otrexup if you:
- Are pregnant or
planning to become pregnant
- Are breastfeeding;
Otrexup can pass into your breast milk and may harm your baby
- Have alcohol
problems (alcoholism)
- Have liver
problems
- Have problems
fighting infection (immunodeficiency syndrome)
- Have been told you
have (or think you have) a blood disorder such as low levels of
whiteblood cells, red blood cells (anemia), or platelets
- Have had an allergy
to methotrexate or any of the ingredients in Otrexup. See
thePrescribing Information for a list of ingredients.
Talk to your doctor before taking this medicine if you have any
of these conditions.
What should I tell my healthcare provider before using
Otrexup?
Before you take Otrexup, tell your doctor if you have any other
medical conditions.
Tell your doctor about all of the medicines you take, including
prescription medicines, over-the-counter medicines, vitamins, and
herbal supplements. Ask your doctor or pharmacist for a list of
medicines if you are not sure. Otrexup may affect how other
medicines work, and other medicines may affect how Otrexup works
causing side effects.
How should I use Otrexup?
- See the
Instructions for Use contained in the Prescribing Information for
detailed information about how to use Otrexup
- Your doctor will
show you or your caregiver how to inject Otrexup. You should not
inject Otrexup until you have been trained on the right way to use
it.
- Inject Otrexup
only 1 time each week. Do not take Otrexup every
day. Taking Otrexup every day may cause death from toxicity.
- If you are not sure
if Otrexup was injected, or if you have hard time giving the
injection, do not inject another dose. Call your
pharmacist or doctor right away
- If you inject too
much Otrexup, call your doctor or go to the nearest hospital
emergency room right away.
What should I avoid while using Otrexup?
- Do not drink alcohol
while taking Otrexup. Drinking alcohol can increase your chances of
getting serious side effects.
- Otrexup can cause
dizziness and tiredness. Do not drive a car, operate machinery, or
do anything that needs you to be alert until you know how Otrexup
affects you.
- Certain vaccinations
should be avoided while taking Otrexup. Talk to your doctor before
you or members of your household receive any vaccines.
What are the possible side effects of
Otrexup?Otrexup may cause serious side effects,
including:
- Fertility
problems. Methotrexate, the active ingredient in Otrexup,
may affect your ability to have a baby. Males may have a decreased
sperm count, and females may have changes to their menstrual cycle.
This can happen while taking Otrexup and for a short period of time
after you stop.
- Certain
cancers. Some people who have taken methotrexate have had
a certain type of cancer called Non-Hodgkin’s lymphoma and other
tumors. Your doctor may tell you to stop taking Otrexup if this
happens.
- Tissue and
bone problems. Taking methotrexate while having radiation
therapy may increase the risk of your tissue or bone not receiving
enough blood. This may lead to death of the tissue or bone.
Common side effects of Otrexup include: nausea,
stomach pain, indigestion (dyspepsia), mouth sores, rash, stuffy or
runny nose and sore throat, diarrhea, abnormal liver function
tests, vomiting, headache, bronchitis, low red, white, and platelet
blood cell count, hair loss, dizziness, sensitivity to light,
burning skin lesions, lung problems.
These are not all the possible side effects of Otrexup. For more
information, ask your doctor or pharmacist.
Tell your doctor if you have any side effect that bothers you or
that does not go away.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call
1-800-FDA-1088.
Please see the full Prescribing Information and Patient
Information for Otrexup at
https://www.Otrexup.com/application/files/3715/8619/3267/Otrexup_USPI_-_LB-0027_V11.pdf
or call 1-855-Otrexup (1-855-687-3987).
About Assertio
Assertio is a specialty pharmaceutical company offering
differentiated products to patients utilizing a non-personal
promotional model. We have built and continue to build our
commercial portfolio by identifying new opportunities within our
existing products as well as acquisitions or licensing of
additional approved products. To learn more about Assertio, visit
www.assertiotx.com.
About BlinkRx
BlinkRx is a unique patient access solution that may help reduce
the barriers to starting and remaining on therapy. Patients benefit
from transparent low prices, free home delivery, and world-class
support.
Investor and Media Contacts
Max NemmersHead, Investor Relations and Administration
investor@assertiotx.com
Allison BaerCommunications & Branding
LeadPress@BlinkRx.com
Forward Looking Statements
Statements in this communication that are not historical facts
are forward-looking statements that reflect Assertio's current
expectations, assumptions and estimates of future performance and
economic conditions. These forward-looking statements are made in
reliance on the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements relate to, among other things, future events or the
future performance or operations of Assertio. All statements other
than historical facts may be forward-looking statements and can be
identified by words such as "anticipate," "believe," "could,"
"design," "estimate," "expect," "forecast," "goal," "guidance,"
"imply," "intend," "may", "objective," "opportunity," "outlook,"
"plan," "position," "potential," "predict," "project,"
"prospective," "pursue," "seek," "should," "strategy," "target,"
"would," "will," "aim" or other similar expressions that convey the
uncertainty of future events or outcomes and are used to identify
forward-looking statements. Such forward-looking statements are not
guarantees of future performance and are subject to risks,
uncertainties and other factors, some of which are beyond the
control of Assertio, including the risks described in Assertio's
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed
with the U.S. Securities and Exchange Commission ("SEC") and in
other filings Assertio makes with the SEC from time to time.
Investors and potential investors are urged not to place undue
reliance on forward-looking statements in this communication, which
speak only as of this date. While Assertio may elect to update
these forward-looking statements at some point in the future, it
specifically disclaims any obligation to update or revise any
forward-looking-statements contained in this press release whether
as a result of new information or future events, except as may be
required by applicable law. Nothing contained herein constitutes or
will be deemed to constitute a forecast, projection or estimate of
the future financial performance or expected results of
Assertio.
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Apr 2024 to May 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From May 2023 to May 2024